Sugi Predict

Sugi Predict / Targets / CDK2

CDK2

Cyclin-dependent kinase 2 · P24941 · CDK2 on Sugi Atlas →

506,058 patent compounds predicted against CDK2, 292,414 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL21169 SCHEMBL21169 0.55 19/20
SCHEMBL20693 SCHEMBL20693 0.53 19/20
SCHEMBL19015 SCHEMBL19015 0.51 19/20
SCHEMBL31357 SCHEMBL31357 0.50 18/20
SCHEMBL31358 SCHEMBL31358 0.50 18/20
SCHEMBL12466 SCHEMBL12466 0.58 16/20
Methylguanine Methylguanine (SCHEMBL34851) 0.51 16/20
SCHEMBL12292 SCHEMBL12292 0.59 15/20
Alvocidib Alvocidib (SCHEMBL3651) 1.00 14/20
Alvocidib Alvocidib (SCHEMBL3652) 1.00 14/20
Purvalanol B Purvalanol B (SCHEMBL27951) 1.00 13/20
2,6-Diaminopurine 2,6-Diaminopurine (SCHEMBL24053) 0.66 11/20
SCHEMBL21483 SCHEMBL21483 0.56 11/20
SCHEMBL20332 SCHEMBL20332 0.52 11/20
SCHEMBL29182 SCHEMBL29182 0.52 11/20
SCHEMBL20155 SCHEMBL20155 0.51 11/20
SCHEMBL22364 SCHEMBL22364 0.50 11/20
Clonazepam Clonazepam (SCHEMBL38899) 0.59 10/20
SCHEMBL20761 SCHEMBL20761 0.52 10/20
SCHEMBL19840 SCHEMBL19840 0.51 10/20

Clinical trials — most relevant to CDK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression PHASE2COMPLETED
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer PHASE2COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Study of AVZO-021 in Patients With Advanced Solid Tumors PHASE1/PHASE2RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer PHASE2RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma PHASE1/PHASE2RECRUITING
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy PHASE2COMPLETED
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6 PHASE2RECRUITING
Palbociclib With Everolimus + Exemestane In BC PHASE1/PHASE2COMPLETED
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. PHASE1/PHASE2COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas PHASE2RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
Avelumab, Palbociclib and Axitinib in Advanced RCC PHASE2WITHDRAWN
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms PHASE1COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors PHASE1COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors PHASE1COMPLETED
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery PHASE1COMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study nanACTIVE_NOT_RECRUITING
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK2 binder may also engage these)

ProteinNameSimilarity
Q5E9Y0 — 1.000 Q5E9Y0 →
P48963 — 1.000 P48963 →
Q63699 — 1.000 Q63699 →
O55076 — 1.000 O55076 →
P23437 — 1.000 P23437 →
P43450 — 1.000 P43450 →
P51166 — 0.999 P51166 →
CDK3 Cyclin-dependent kinase 3 0.999 landscape →
P23111 — 0.999 P23111 →
Q80YP0 — 0.998 Q80YP0 →
P29619 — 0.998 P29619 →
Q9W739 — 0.997 Q9W739 →
P24100 — 0.997 P24100 →
Q05006 — 0.997 Q05006 →
Q5RCH1 — 0.997 Q5RCH1 →
Q03114 — 0.997 Q03114 →
Q41639 — 0.996 Q41639 →
Q38773 — 0.996 Q38773 →
Q2PQN9 — 0.996 Q2PQN9 →
Q9DGD3 — 0.996 Q9DGD3 →
P34112 — 0.996 P34112 →
Q26671 — 0.996 Q26671 →
P34117 — 0.995 P34117 →
Q38772 — 0.995 Q38772 →
P04551 — 0.995 P04551 →
P52389 — 0.994 P52389 →
CDK1 Cyclin-dependent kinase 1 0.994 landscape →
Q27032 — 0.994 Q27032 →
P24923 — 0.993 P24923 →
Q9DGA5 — 0.993 Q9DGA5 →